HugoFernandezMD
Hematology • Hollywood, FLHematologic Oncology, Myeloproliferative Disorder Hematology-Oncology
Professor, Oncologic Sciences, USF-Morsani
Dr. Fernandez is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
603 N Flamingo Rd
Ste 151
Hollywood, FL 33028Phone+1 954-265-4325Fax+1 954-443-4747
Summary
- Hugo Fernandez, MD, based in Hollywood, FL, specializes in Hematology with subspecialties in Hematologic Oncology and Myeloproliferative Disorder Hematology-Oncology. He completed his education at the University of Florida College of Medicine, followed by a residency and fellowship at the University of Miami/Jackson Health System. His expertise includes amyloidosis, hematologic oncology, bone marrow failure syndromes, myelodysplasia, and myelofibrosis. Dr. Fernandez has several publications focused on transplantation therapies and leukemia, and engages in clinical trials involving graft-versus-host disease and leukemia treatments.
Education & Training
University of Miami/Jackson Health SystemFellowship, Hematology and Medical Oncology, 1991 - 1994- University of Miami/Jackson Health SystemResidency, Internal Medicine, 1987 - 1991
University of Florida College of MedicineClass of 1987
Certifications & Licensure
FL State Medical License 1988 - 2027
American Board of Internal Medicine Hematology
Clinical Trials
- Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia Start of enrollment: 2002 Dec 19
- Dosing Study of Ara-C/EL625/Idarubicin in Refractory and Relapsed AML Start of enrollment: 2004 Apr 01
- Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
- Join now to see all
Publications & Presentations
PubMed
- Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukem...Omar Albanyan, Hany Elmariah, Denise Kalos, Jongphil Kim, Rawan Faramand
Transplantation and Cellular Therapy. 2024-11-01 - 2 citationsLower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosp...Hany Elmariah, Salman Otoukesh, Ambuj Kumar, Haris Ali, Shukaib Arslan
Transplantation and Cellular Therapy. 2024-10-01 - 7 citationsSirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Pos...Hany Elmariah, Salman Otoukesh, Ambuj Kumar, Haris Ali, Shukaib Arslan
Transplantation and Cellular Therapy. 2024-02-01
Abstracts/Posters
- Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid LeukemiaHugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Comparison of Overall Responses after Standard Induction with High Dose Daunorubicin Versus Standard Dose Daunorubicin with Gemtuzumab Ozogamicin in Favorable Risk Acu...Hugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Hypomethylating Agent and Venetoclax Combination Yields Comparable Outcomes to CPX-351 in Newly Diagnosed Acute Myeloid LeukemiaHugo F. Fernandez, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Press Mentions
New Memorial Cancer Institute Puts World-Class Care Under One RoofOctober 19th, 2023- Health | Memorial Healthcare Unveils Its New, High-Tech Cancer Center in West BrowardNovember 24th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
